急性片頭痛薬の世界市場 - 薬剤タイプ別（エルゴットアルカロイド、鎮痛薬、トリプタン、その他）、投与経路別、入手可能性別、地域別、国別の分析：市場規模、洞察、競合、Covid-19の影響と予測（2023-2028年）

Global Acute Migraine Drugs Market - Analysis By Drug Type (Ergot Alkaloids, Analgesics, Triptans, Others), Route of Administration, Availability, By Region, By Country: Market Size, Insights, Competition, Covid-19 Impact and Forecast (2023-2028)

エグゼクティブ・サマリー世界の急性片頭痛薬市場は2021年に84億米ドル規模に達し、2023年から2028年にかけて年平均成長率7.82％で拡大すると予測されている。労働人口の片頭痛有病率の上昇と医療費の増加が... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Azoth Analytics アーゾスアナリティクス	2023年2月28日	US$2,800 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	260	英語

サマリー

エグゼクティブ・サマリー

世界の急性片頭痛薬市場は2021年に84億米ドル規模に達し、2023年から2028年にかけて年平均成長率7.82％で拡大すると予測されている。労働人口の片頭痛有病率の上昇と医療費の増加が、急性片頭痛薬の需要を押し上げている。

トリプタンは選択的セロトニン受容体作動薬であるため、片頭痛治療薬として広く使用されている。脳内のセロトニン濃度を上昇させ、炎症を抑え、血管を収縮させることで頭痛や片頭痛を終わらせる。2021年の薬剤タイプ別市場シェアでは、トリプタン系薬剤が全体の約46%を占めている。片頭痛の軽い痛みの治療には、ナプロキセン、イブプロフェン、アスピリン、アセトアミノフェン、プソイドエフェドリン、フェニレフリンなどの市販薬が広く利用されている。

片頭痛に苦しむ患者やトリプタンの限界から、急性片頭痛の治療には大きな可能性がある。このシナリオでは、Ubrelvy、Reyvow、Nurtec ODTを含む多くの新規治療オプションがある。しかし、大きく進出している治療法のひとつが、インペルのTrudhesaである。Trudhesaは、DHEを経鼻投与する自己投与型薬剤装置である。Trudhesaは2021年9月にFDAによって承認された。

片頭痛患者の約4分の3は女性である。20歳から45歳の女性が最も片頭痛に悩まされやすい。さらに、女性のホルモンの変動が片頭痛の引き金になることもあり、月経時片頭痛は女性の片頭痛患者の約60％が罹患している。アメリカ大陸は2021年に金額ベースで市場の主要シェアを占め、同地域は急性片頭痛薬の売上高全体で最大のシェアを維持し続けると予想される。

レポートの範囲

- 本レポートでは、急性片頭痛薬市場を金額（10億米ドル）別に分析しています。

- 過去期間2018-2021年、基準年2022年、予測期間2023-2028年の急性片頭痛薬市場の分析を掲載しています。

- 急性片頭痛薬市場を薬剤タイプ別（エルゴットアルカロイド、鎮痛薬、トリプタン、香料、その他薬剤タイプ）に分析したレポートです。

- 急性片頭痛薬市場を投与経路別（静脈内投与、経口投与、経鼻投与、その他投与経路）に分析しています。

- 急性片頭痛薬市場を入手可能性別（市販薬、処方薬）に分析

- 急性片頭痛薬の世界市場を国別（米国、カナダ、ドイツ、英国、フランス、イタリア、スペイン、中国、日本、インド）に分析しています。

- 本レポートの主要な洞察は、SWOTおよびポーターのファイブフォース分析の枠組みを通して提示されています。また、市場の魅力を地域別、薬剤タイプ別、入手可能性別に紹介しています。

- また、業界の主な機会、動向、促進要因、課題についても分析しています。

- 本レポートでは、競合の動向、戦略、M&A、新製品開発などを追跡しています。本レポートに掲載されている企業は、イーライリリー・アンド・カンパニー、GSK plc.、バイエルAG、ジョンソン・エンド・ジョンソン、テバ・ファーマシューティカル・インダストリーズ・リミテッド、アッヴィ・インク、ノバルティス、メルク・アンド・カンパニー、ファイザー、ベーリンガーインゲルハイムなどです。

主なターゲットオーディエンス

- ヘルスケアおよび製薬企業

- 反復性片頭痛患者

- 主要な急性片頭痛治療薬ブランド

- 研究開発機関

ページTOPに戻る

1. Market Background

1.1 Scope and Product Outlook

1.2 Executive Summary

1.3 Research Methodology

2. Strategic Recommendations

3. Global Acute Migraine Drugs Market: Historic and Forecast (2018-2028)

3.1 Impact Analysis of Macro Economic Factors on Acute Migraine Drugs Market

3.2 Global Acute Migraine Drugs Market: Ecosystem Analysis

3.2.1 Migraine: Fact sheet

3.2.2 Migraine – Nurtec ODT and Ubrelvy patient’s Therapy abandonment data

3.2.3 Pipeline scenario of Acute Migraine Drugs

3.2.4 Annual Sales of Triptans and Non Triptans in the U.S

3.3 Global Acute Migraine Drugs Market: Dashboard

3.4 Global Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)

3.5 Impact of COVID-19 on Acute Migraine Drugs Market

3.6 Global Acute Migraine Drugs Market Segmentation: By Drug Type (2018-2028)

3.6.1 Global Acute Migraine Drugs Market, By Drug Type Overview

3.6.2 Global Acute Migraine Drugs Market Size, By Ergot Alkaloids, By Value, 2018H-2028F (USD Billion & CAGR)

3.6.3 Global Acute Migraine Drugs Market Size, By Analgesics, By Value, 2018H-2028F (USD Billion & CAGR)

3.6.4 Global Acute Migraine Drugs Market Size, By Triptans, By Value, 2018H-2028F (USD Billion & CAGR)

3.6.5 Global Acute Migraine Drugs Market Size, By Other Drug Types, By Value, 2018H-2028F (USD Billion & CAGR)

3.7 Global Acute Migraine Drugs Market Segmentation: By Route of Administration

3.7.1 Global Acute Migraine Drugs Market, By Route of Administration Overview

3.7.2 Global Acute Migraine Drugs Market Size, By Intravenous, By Value, 2018H-2028F (USD Billion & CAGR)

3.7.3 Global Acute Migraine Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)

3.7.4 Global Acute Migraine Drugs Market Size, By Nasal, By Value, 2018H-2028F (USD Billion & CAGR)

3.7.5 Global Acute Migraine Drugs Market Size, By Other Routes of Administration, By Value, 2018H-2028F (USD Billion & CAGR)

3.8 Global Acute Migraine Drugs Market Segmentation: By Availability

3.8.1 Global Acute Migraine Drugs Market, By Availability Overview

3.8.2 Global Acute Migraine Drugs Market Size, By Over The Counter, By Value, 2018H-2028F (USD Billion & CAGR)

3.8.3 Global Acute Migraine Drugs Market Size, By Prescription, By Value, 2018H-2028F (USD Billion & CAGR)

4. Global Acute Migraine Drugs Market, Regional Analysis (2018-2028)

4.1 Regional Coverage of the Study

4.2 Regional Snapshot

5. Americas Acute Migraine Drugs Market: Historic and Forecast (2018-2028)

5.1 Americas Acute Migraine Drugs Market: Snapshot

5.2 Americas Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)

5.3 Americas Acute Migraine Drugs Market: Key Factors

5.4 Americas Acute Migraine Drugs Market Segmentation: By Drug Type

5.4.1 Americas Acute Migraine Drugs Market, By Drug Type Overview

5.4.2 Americas Acute Migraine Drugs Market Size, By Ergot Alkaloids, By Value, 2018H-2028F (USD Billion & CAGR)

5.4.3 Americas Acute Migraine Drugs Market Size, By Analgesics, By Value, 2018H-2028F (USD Billion & CAGR)

5.4.4 Americas Acute Migraine Drugs Market Size, By Triptans, By Value, 2018H-2028F (USD Billion & CAGR)

5.4.5 Americas Acute Migraine Drugs Market Size, By Other Drug Types, By Value, 2018H-2028F (USD Billion & CAGR)

5.5 Americas Acute Migraine Drugs Market Segmentation: By Route of Administration

5.5.1 Americas Acute Migraine Drugs Market, By Route of Administration Overview

5.5.2 Americas Acute Migraine Drugs Market Size, By Intravenous, By Value, 2018H-2028F (USD Billion & CAGR)

5.5.3 Americas Acute Migraine Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)

5.5.4 Americas Acute Migraine Drugs Market Size, By Nasal, By Value, 2018H-2028F (USD Billion & CAGR)

5.5.5 Americas Acute Migraine Drugs Market Size, By Other Routes of Administration, By Value, 2018H-2028F (USD Billion & CAGR)

5.6 Americas Acute Migraine Drugs Market Segmentation: By Availability

5.6.1 Americas Acute Migraine Drugs Market, By Availability Overview

5.6.2 Americas Acute Migraine Drugs Market Size, By By Over The Counter, By Value, 2018H-2028F (USD Billion & CAGR)

5.6.3 Americas Acute Migraine Drugs Market Size, By Prescription, By Value, 2018H-2028F (USD Billion & CAGR)

5.7 Americas Acute Migraine Drugs Market Segmentation: By Country

5.7.1 Americas Acute Migraine Drugs Market Segmentation, By Country Overview

5.7.2 United States Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)

5.7.2.1 United States Acute Migraine Drugs Market, By Drug Type

5.7.2.2 United States Acute Migraine Drugs Market, By Route of Administration

5.7.2.3 United States Acute Migraine Drugs Market, By Availability

5.7.3 Canada Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)

5.7.3.1 Canada Acute Migraine Drugs Market, By Drug Type

5.7.3.2 Canada Acute Migraine Drugs Market, By Route of Administration

5.7.3.3 Canada Acute Migraine Drugs Market, By Availability

5.7.4 Rest of Americas Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)

5.7.4.1 Rest of Americas Acute Migraine Drugs Market, By Drug Type

5.7.4.2 Rest of Americas Acute Migraine Drugs Market, By Route of Administration

5.7.4.3 Rest of Americas Acute Migraine Drugs Market, By Availability

6. Europe Acute Migraine Drugs Market: Historic and Forecast (2018-2028)

6.1 Europe Acute Migraine Drugs Market: Snapshot

6.2 Europe Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)

6.3 Europe Acute Migraine Drugs Market: Key Factors

6.4 Europe Acute Migraine Drugs Market Segmentation: By Drug Type

6.4.1 Europe Acute Migraine Drugs Market, By Drug Type Overview

6.4.2 Europe Acute Migraine Drugs Market Size, By Ergot Alkaloids, By Value, 2018H-2028F (USD Billion & CAGR)

6.4.3 Europe Acute Migraine Drugs Market Size, By Analgesics, By Value, 2018H-2028F (USD Billion & CAGR)

6.4.4 Europe Acute Migraine Drugs Market Size, By Triptans, By Value, 2018H-2028F (USD Billion & CAGR)

6.4.5 Europe Acute Migraine Drugs Market Size, By Other Drug Types, By Value, 2018H-2028F (USD Billion & CAGR)

6.5 Europe Acute Migraine Drugs Market Segmentation: By Route of Administration

6.5.1 Europe Acute Migraine Drugs Market, By Route of Administration Overview

6.5.2 Europe Acute Migraine Drugs Market Size, By Intravenous, By Value, 2018H-2028F (USD Billion & CAGR)

6.5.3 Europe Acute Migraine Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)

6.5.4 Europe Acute Migraine Drugs Market Size, By Nasal, By Value, 2018H-2028F (USD Billion & CAGR)

6.5.5 Europe Acute Migraine Drugs Market Size, By Other Routes of Administration, By Value, 2018H-2028F (USD Billion & CAGR)

6.6 Europe Acute Migraine Drugs Market Segmentation: By Availability

6.6.1 Europe Acute Migraine Drugs Market, By Availability Overview

6.6.2 Europe Acute Migraine Drugs Market Size, By By Over The Counter, By Value, 2018H-2028F (USD Billion & CAGR)

6.6.3 Europe Acute Migraine Drugs Market Size, By Prescription, By Value, 2018H-2028F (USD Billion & CAGR)

6.7 Europe Acute Migraine Drugs Market Segmentation: By Country

6.7.1 Europe Acute Migraine Drugs Market Segmentation, By Country, Overview

6.7.2 Germany Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)

6.7.2.1 Germany Acute Migraine Drugs Market, By Drug Type

6.7.2.2 Germany Acute Migraine Drugs Market, By Route of Administration

6.7.2.3 Germany Acute Migraine Drugs Market, By Availability

6.7.3 United Kingdom Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)

6.7.3.1 United Kingdom Acute Migraine Drugs Market, By Drug Type

6.7.3.2 United Kingdom Acute Migraine Drugs Market, By Route of Administration

6.7.3.3 United Kingdom Acute Migraine Drugs Market, By Availability

6.7.4 France Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)

6.7.4.1 France Acute Migraine Drugs Market, By Drug Type

6.7.4.2 France Acute Migraine Drugs Market, By Route of Administration

6.7.4.3 France Acute Migraine Drugs Market, By Availability

6.7.5 Italy Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)

6.7.5.1 Italy Acute Migraine Drugs Market, By Drug Type

6.7.5.2 Italy Acute Migraine Drugs Market, By Route of Administration

6.7.5.3 Italy Acute Migraine Drugs Market, By Availability

6.7.6 Spain Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)

6.7.6.1 Spain Acute Migraine Drugs Market, By Drug Type

6.7.6.2 Spain Acute Migraine Drugs Market, By Route of Administration

6.7.6.3 Spain Acute Migraine Drugs Market, By Availability

6.7.7 Rest of Europe Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)

6.7.7.1 Rest of Europe Acute Migraine Drugs Market, By Drug Type

6.7.7.2 Rest of Europe Acute Migraine Drugs Market, By Route of Administration

6.7.7.3 Rest of Europe Acute Migraine Drugs Market, By Availability

7. Asia Pacific Acute Migraine Drugs Market: Historic and Forecast (2018-2028)

7.1 Asia Pacific Acute Migraine Drugs Market: Snapshot

7.2 Asia Pacific Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)

7.3 Asia Pacific Acute Migraine Drugs Market: Key Factors

7.4 Asia Pacific Acute Migraine Drugs Market Segmentation: By Drug Type

7.4.1 Asia Pacific Acute Migraine Drugs Market, By Drug Type Overview

7.4.2 Asia Pacific Acute Migraine Drugs Market Size, By Ergot Alkaloids, By Value, 2018H-2028F (USD Billion & CAGR)

7.4.3 Asia Pacific Acute Migraine Drugs Market Size, By Analgesics, By Value, 2018H-2028F (USD Billion & CAGR)

7.4.4 Asia Pacific Acute Migraine Drugs Market Size, By Triptans, By Value, 2018H-2028F (USD Billion & CAGR)

7.4.5 Asia Pacific Acute Migraine Drugs Market Size, By Other Drug Types, By Value, 2018H-2028F (USD Billion & CAGR)

7.5 Asia Pacific Acute Migraine Drugs Market Segmentation: By Route of Administration

7.5.1 Asia Pacific Acute Migraine Drugs Market, By Route of Administration Overview

7.5.2 Asia Pacific Acute Migraine Drugs Market Size, By Intravenous, By Value, 2018H-2028F (USD Billion & CAGR)

7.5.3 Asia Pacific Acute Migraine Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)

7.5.4 Asia Pacific Acute Migraine Drugs Market Size, By Nasal, By Value, 2018H-2028F (USD Billion & CAGR)

7.5.5 Asia Pacific Acute Migraine Drugs Market Size, By Other Routes of Administration, By Value, 2018H-2028F (USD Billion & CAGR)

7.6 Asia Pacific Acute Migraine Drugs Market Segmentation: By Availability

7.6.1 Asia Pacific Acute Migraine Drugs Market, By Availability Overview

7.6.2 Asia Pacific Acute Migraine Drugs Market Size, By Over the Counter, By Value, 2018H-2028F (USD Billion & CAGR)

7.6.3 Asia Pacific Acute Migraine Drugs Market Size, By Prescription, By Value, 2018H-2028F (USD Billion & CAGR)

7.7 Asia Pacific Acute Migraine Drugs Market Segmentation: By Country

7.7.1 Asia Pacific Acute Migraine Drugs Market, By Country Overview

7.7.2 China Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)

7.7.2.1 China Acute Migraine Drugs Market, By Drug Type

7.7.2.2 China Acute Migraine Drugs Market, By Route of Administration

7.7.2.3 China Acute Migraine Drugs Market, By Availability

7.7.3 Japan Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)

7.7.3.1 Japan Acute Migraine Drugs Market, By Drug Type

7.7.3.2 Japan Acute Migraine Drugs Market, By Route of Administration

7.7.3.3 Japan Acute Migraine Drugs Market, By Availability

7.7.4 India Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)

7.7.4.1 India Acute Migraine Drugs Market, By Drug Type

7.7.4.2 India Acute Migraine Drugs Market, By Route of Administration

7.7.4.3 India Acute Migraine Drugs Market, By Availability

7.7.5 Rest Of Asia Pacific Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)

7.7.5.1 Rest Of Asia Pacific Acute Migraine Drugs Market, By Drug Type

7.7.5.2 Rest Of Asia Pacific Acute Migraine Drugs Market, By Route of Administration

7.7.5.3 Rest Of Asia Pacific Acute Migraine Drugs Market, By Availability

8. Middle East & Africa Acute Migraine Drugs Market: Historic and Forecast (2018-2028)

8.1 Middle East & Africa Acute Migraine Drugs Market: Snapshot

8.2 Middle East & Africa Acute Migraine Drugs Market: Market Size and CAGR, 2018-2028 (USD Billion & CAGR)

8.3 Middle East & Africa Acute Migraine Drugs Market: Key Factors

8.4 Middle East & Africa Acute Migraine Drugs Market Segmentation: By Drug Type

8.4.1 Middle East & Africa Acute Migraine Drugs Market, By Drug Type Overview

8.4.2 Middle East & Africa Acute Migraine Drugs Market Size, By Ergot Alkaloids, By Value, 2018H-2028F (USD Billion & CAGR)

8.4.3 Middle East & Africa Acute Migraine Drugs Market Size, By Analgesics, By Value, 2018H-2028F (USD Billion & CAGR)

8.4.4 Middle East & Africa Acute Migraine Drugs Market Size, By Triptans, By Value, 2018H-2028F (USD Billion & CAGR)

8.4.5 Middle East & Africa Acute Migraine Drugs Market Size, By Other Drug Types, By Value, 2018H-2028F (USD Billion & CAGR)

8.5 Middle East & Africa Acute Migraine Drugs Market Segmentation: By Route of Administration

8.5.1 Middle East & Africa Acute Migraine Drugs Market, By Route of Administration Overview

8.5.1 Middle East & Africa Acute Migraine Drugs Market Size, By Intravenous, By Value, 2018H-2028F (USD Billion & CAGR)

8.5.1 Middle East & Africa Acute Migraine Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)

8.5.1 Middle East & Africa Acute Migraine Drugs Market Size, By Nasal, By Value, 2018H-2028F (USD Billion & CAGR)

8.5.1 Middle East & Africa Acute Migraine Drugs Market Size, By Other Routes of Administration, By Value, 2018H-2028F (USD Billion & CAGR)

8.6 Middle East & Africa Acute Migraine Drugs Market Segmentation: By Availability

8.6.1 Middle East & Africa Acute Migraine Drugs Market, By Availability Overview

8.6.2 Middle East & Africa Acute Migraine Drugs Market Size, By Over the Counter, By Value, 2018H-2028F (USD Billion & CAGR)

8.6.3 Middle East & Africa Acute Migraine Drugs Market Size, By Prescription, By Value, 2018H-2028F (USD Billion & CAGR)

9. Market Dynamics

9.1 Impact assessment of Market Dynamics on Global Acute Migraine Drugs Market

9.2 Drivers

9.3 Restraints

9.4 Trends

10. Industry Ecosystem Analysis

10.1 Macro-Economic Factor Assessment

10.2 Value Chain Analysis

10.3 Porter’s Five Forces Model

11. Competitive Positioning

11.1 Companies’ Product Positioning

11.2 Market Position Matrix

11.3 Market Share Analysis of Acute Migraine Drugs Market

11.4 Company Profiles

11.4.1 Eli Lilly and Company

11.4.2 GSK plc.

11.4.3 Bayer AG

11.4.4 Johnson & Johnson

11.4.5 Teva Pharmaceutical Industries Ltd.

11.4.6 AbbVie Inc.

11.4.7 Novartis

11.4.8 Merck & Co., Inc.

11.4.9 Pfizer Inc.

11.4.10 Boehringer Ingelheim

12. About Us & Disclaimer

ページTOPに戻る

Table of Contents

Summary

Executive Summary

The global Acute Migraine Drugs market was worth USD 8.40 billion in 2021 and is anticipated to expand at a CAGR of 7.82% between 2023 and 2028. The rising prevalence of migraine among the working population, as well as increasing healthcare expenditure, are driving up demand for acute migraine medications.

Triptans are widely used migraine medications because they are selective serotonin receptor agonists. They work by increasing serotonin levels in the brain, which reduces inflammation and constricts blood vessels, thereby ending the headache or migraine. Triptans account for approximately 46% of the overall market share by drug type segment in 2021. For Mild pain treatment of Migraine, over-the-counter medications such as Naproxen, Ibuprofen, Aspirin, Acetaminophen, Pseudoephedrine, or phenylephrine are widely utilized.

With patients’ suffering from migraine and the limitations of triptan, there are significant opportunities in the treatment of acute migraine. In this scenario, there are a number of novel therapeutic options that include Ubrelvy, Reyvow and Nurtec ODT. However, one of the treatments making huge inroads is Impel's Trudhesa, which is a self-administered drug device for the intranasal delivery of DHE. Trudhesa was approved by the FDA in September 2021.

Women account for about three-quarters of all migraine cases. Women aged 20 to 45 are the most prone to suffer from migraines. Moreover, hormonal variations in women may be a migraine trigger, and menstrual migraines affect around 60% of female migraineurs. The Americas accounted for a major share of the market in terms of value in 2021 and the region is expected to keep retaining the largest share of the overall sales of acute migraine drugs.

Scope of the Report

• The report analyses the Acute Migraine Drugs Market by Value (USD Billion).

• The report presents the analysis of the Acute Migraine Drugs market for the historical period of 2018-2021, the base year 2022 and the forecast period of 2023-2028.

• The report analyses the Acute Migraine Drugs Market by Drug Type (Ergot Alkaloids, Analgesics, Triptans, Fragrance, Other Drug Types)

• The report analyses the Acute Migraine Drugs Market By Route of Administration (Intravenous, Oral, Nasal, Other Routes of Administration)

• The report analyses the Acute Migraine Drugs Market By Availability (Over the Counter, Prescription)

• The Global Acute Migraine Drugs Market has been analysed by countries (United States, Canada, Germany, UK, France, Italy, Spain, China, Japan, India).

• The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Drug Type and Availability

• Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies profiled in the report include Eli Lilly and Company, GSK plc., Bayer AG, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Novartis, Merck & Co., Inc., Pfizer Inc., Boehringer Ingelheim.

Key Target Audience

• Healthcare and Pharmaceutical Companies

• Episodic migraine Patients

• Leading Acute Migraine Drugs Brands

• Research & Development Organizations

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（その他）の最新刊レポート

Azoth Analytics 社の最新刊レポート

本レポートと同じKEY WORD（acute）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

急性片頭痛薬の世界市場 - 薬剤タイプ別（エルゴットアルカロイド、鎮痛薬、トリプタン、その他）、投与経路別、入手可能性別、地域別、国別の分析：市場規模、洞察、競合、Covid-19の影響と予測（2023-2028年）

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（その他）の最新刊レポート

Azoth Analytics 社の最新刊レポート

本レポートと同じKEY WORD（acute）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?